Extended-Spectrum-Beta-Lactamases, AmpC Beta-Lactamases and Plasmid Mediated Quinolone Resistance in Klebsiella spp. from Companion Animals in Italy

Donati, Valentina; Feltrin, Fabiola; Hendriksen, Rene S.; Svendsen, Christina Aaby; Cordaro, Gessica; Garcia-Fernandez, Aurora; Lorenzetti, Serena; Lorenzetti, Raniero; Battisti, Antonio; Franco, Alessia

Published in: PLOS ONE

Link to article, DOI: 10.1371/journal.pone.0090564

Publication date: 2014

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
Extended-Spectrum-Beta-Lactamases, AmpC Beta-Lactamases and Plasmid Mediated Quinolone Resistance in *Klebsiella* spp. from Companion Animals in Italy

Valentina Donati¹, Fabiola Feltrin¹, Rene S. Hendriksen², Christina Aaby Svendsen², Gessica Cordaro¹, Aurora García-Fernández³, Serena Lorenzetti¹, Raniero Lorenzetti¹, Antonio Battisti¹*, Alessia Franco¹

1 Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana, Rome, Italy, 2 Technical University of Denmark, National Food Institute (DTU-Food), Kongens Lyngby, Denmark, 3 Istituto Superiore di Sanità, Department of Infectious, Parasitic and Immune-Mediated Diseases, Rome, Italy

Abstract

We report the genetic characterization of 15 *Klebsiella pneumoniae* (KP) and 4 isolates of *K. oxytoca* (KO) from clinical cases in dogs and cats showing extended-spectrum cephalosporin (ESC) resistance. Extended spectrum beta-lactamase (ESBL) and AmpC genes, plasmid-mediated quinolone resistance (PMQR) and co-resistances were investigated. Among KP isolates, ST101 clone was predominant (8/15, 53%), followed by ST15 (4/15, 27%). ST11 and ST340, belonging to Clonal Complex (CC)11, were detected in 2012 (3/15, 20%). MLST on KP isolates corresponded well with PFGE results, with 11 different PFGE patterns observed, including two clusters of two (ST340) and four (ST101) indistinguishable isolates, respectively. All isolates harbored at least one ESBL or AmpC gene, all carried on transferable plasmids (IncN, IncFII, IncI1, IncN), and 16/19 were positive for PMQR genes (*qnr* family or *aac(6’)-Ib-cr*). The most frequent ESC was CTX-M-15 (11/19, 58%), detected in all KP ST101, in one KP ST15 and in both KP ST340. *bla*<sub>CTX-M-15</sub> was carried on IncN plasmids in all but one KP isolate. All KP ST15 isolates harbored different ESC resistance genes and different plasmids, and presented the non-transferable *bla*<sub>SHV-28</sub> gene, in association with *bla*<sub>CTX-M-15</sub>, *bla*<sub>CTX-M-11</sub> (on IncR, or on IncN), *bla*<sub>SHV-26</sub> (on IncR) or *bla*<sub>SHV-2</sub> genes (on IncI1). KO isolates were positive for *bla*<sub>CTX-M-15</sub>-gene (on IncI2), or for the *bla*<sub>SHV-12</sub> and *bla*<sub>SHV-14</sub>-genes (on IncL/M). They were all positive for *qnr* genes, and one also for the *aac(6’)-Ib-cr* gene. All *Klebsiella* isolates showed multiresistance towards aminoglycosides, sulfonamides, tetracyclines, trimethoprim and amphenicols, mediated by *strA/B, aadA2, aadB*, and (2’)-*Ia, aac(6’)-Ib*, *sul*, *tet*, *dfr* and *cat* genes in various combinations. The emergence in pets of multidrug-resistant *Klebsiella* with ESBL, AmpC and PMQR determinants, poses further and serious challenges in companion animal therapy and raise concerns for possible bidirectional transmission between pets and humans, especially at household level.


Editor: Axel Cloeckaert, Institut National de la Recherche Agronomique, France

Received December 24, 2013; Accepted February 3, 2014; Published March 4, 2014

Copyright: © 2014 Donati et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: antonio.battisti@izsl.it

Introduction

*Klebsiella* are bacterial pathogens that can cause a variety of severe infections in humans, mainly due to *K. pneumoniae* (KP) [1], [2] and to a lesser degree to *K. oxytoca* (KO) [3], [4]. KP is also a well-known causal agent of mastitis in cattle and bacteremia in calves, cervicitis and metritis in mares, pneumonia and septicemia in foals, pneumonia, urinary tract infection (UTI) and septicemia in dogs [5], [6], [7].

Increasing antimicrobial resistance, especially towards aminoglycosides, (fluoro)quinolones, third and fourth generation cephalosporins, cephemycins, and carbapenems have been reported in the last decade [8], [9], [10], and poses serious therapeutic problems when treating *Klebsiella* infections in humans. In veterinary medicine, scarce information is reported on the occurrence of extended spectrum beta-lactamases (ESBLs), AmpC beta-lactamases and plasmid mediated quinolone resistance (PMQR) in *Klebsiella* isolates from companion animals [11], [12]. The aim of the study was to provide molecular characterization of extended-spectrum cephalosporin (ESC) resistance and PMQR in *Klebsiella* isolates from clinical cases or lesions in necropsied animals of canine and feline origin in Italy. A further aim was to determine phenotype and genotype of co-resistances, and to provide plasmid identification and genetic relatedness by Multi-locus Sequence Typing (MLST) and Pulsed Field Gel Electrophoresis (PFGE) among the isolates, to evaluate potential clustering of ESC, PMQR, and other resistance genes among clones.

Materials and Methods

Origin of ESC-resistant *Klebsiella*

Between 2006 and 2012, the Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana (IZSLT) investigated samples from 1535 dogs and 429 cats of clinical cases and necropsy specimens with suspicious bacterial infections, submitted by veterinarians practising mainly in central Italy, and some practising in northern Italy. Presumptive positive *Klebsiella* isolates were identified using the API 20E identification system (bioMérieux, Graponne, France). For species-level identification of isolates
with phenotypic inconclusive results 16S rDNA sequencing technique was employed, by means of the MicroSeq Full Gene system (Applied Biosystems, USA) as described previously [13].

Genotypic characterization

Multilocus Sequence Typing on KP isolates was performed as previously described [14], and interpreted according to the KP MLST database (www.pasteur.fr/mlst).

In addition, all isolates were genotyped by PFGE using XbaI according to the previously published protocol [15].

Antimicrobial susceptibility testing

Antimicrobial susceptibility testing was performed as minimum inhibitory concentrations (MIC) by micro-broth dilution in 96-well microtitre plates [Trek Diagnostic Systems, Westlake, OH, USA]. The following antimicrobials were tested: ampicillin, cefotaxime, cefazidime, ciprofloxacin, chloramphenicol, florfenicol, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfonamides, tetracycline, and trimethoprim. The results were interpreted according to the European Committee on Antibiotic Susceptibility Testing (EUCAST) epidemiological cut-offs (www.euCAST.org) and to Clinical Laboratory Standard Institute [16] or EUCAST clinical breakpoints for those drugs for which epidemiological cut-offs have not been made available (kanamycin, chloramphenicol, sulfamethoxazole, trimethoprim). For streptomycin, a cut-off of 16 mg/L was used, according to EUCAST MIC distributions.

Confirmatory test for the detection of ESBLs were performed on isolates resistant to cefotaxime or cefazidime according to Clinical Laboratory Standard Institute (CLSI) recommendations [16].

Detection of genes encoding beta-lactamase and PMQR

For the confirmed ESBL producing isolates, the encoding genes belonging to the beta-lactamase and PMQR families were further analyzed for the presence of bla<sub>CTX-M</sub> [17], bla<sub>SHV</sub> [18], bla<sub>TEM</sub> [19], bla<sub>OXA</sub> [20], bla<sub>AmpC</sub> families [21], as well as for genes of the <i>qnr</i> family, <i>qepA</i>, and <i>aac(6’)-Ib-cr</i> encoding for PMQR [22], [23], [24], [25], [26]. The isolates were further screened by PCR for genes encoding carbapenemases [27]. Amplicons were sequenced by BigDye Terminator chemistry (Applied Biosystems, Foster City, CA, USA) and migrated with an automated sequencer (ABI Prism 310; Applied Biosystems). Sequence data analysis was performed using CLC DNA workbench software version 5.7.1 (CLC Bio, Aarhus, Denmark) and evaluated against the GenBank nucleotide databases.

Detection of plasmid replicons

Identification of plasmids was performed by PCR-based replicon typing as previously described [28], [29], [30], and using the PBRT kit (Diatheva, Fano, Italy).

Plasmid analysis

Plasmid DNA preparations were performed using the NucleoSpin Plasmid/Plasmid (NoLD) kit (Macherey-Nagel, Düren, Deutschland) and used to transform MAX Efficiency DH5α Competent Cells (Invitrogen, Life Technologies, U.S.A). In order to identify the plasmid carrying the ESBLs and AmpC genes, the selection of the transformants was performed on LB agar plates containing 100 µg/ml ampicillin.

Additionally, the isolates were tested according to the manufacturer’s instructions using an array hybridization kit for DNA-based detection of the most common resistance genes, and for the integrase gene (<i>intI1</i>) of class 1 integrons of Gram negative bacteria (Alere Technologies GmbH, Jena, Germany) and the results interpreted by the ArrayMate, Alere.

Results

Isolation rates

The samples (n = 1984; dogs and cats) yielded a total 70 (3.53%, 95% CI: 2.72%–4.34%) KP and 23 (1.16%), 95% CI: 0.69%–1.63%) KO among the isolates, respectively. Of these, 15 (21.4%) KP and four (17.4%) KO revealed resistance to ESC and were investigated in this study.

Genetic relatedness

The 15 KP isolates investigated by MLST were assigned to four different Sequence Types (ST): ST11 (n = 1), ST340 (n = 2), ST101 (n = 8), and ST15 (n = 4) (Figure 1). ST11 and its single-locus (<i>ssuR</i>) variant (SLV) ST340 (3/15, 20%), both belonging to CG11, were detected in 2012. The separation of the isolates based on MLST corresponded well with PFGE results grouping the same isolates (Figure 1). A total of 11 different PFGE patterns were observed including two clusters of two and four indistinguishable isolates, respectively (Figure 1). The cluster of the two isolates both belonged to ST340 and was related (80% similarity) to a single isolate exhibiting a unique PFGE pattern and belonging to ST11. The other cluster of four indistinguishable isolates was highly related (from 99% to 80% similarity) to additional four isolates within the same PFGE group, all belonging to ST101 (Figure 1). No clustering was observed related to time, animal origin, nor infection, but some to the presence of resistance genes (Table 1). No MLST was assigned to the four KO isolates. However, the four isolates revealed three different PFGE patterns of which one was a cluster of two identical isolates (Figure 2). The three patterns seemed not to be related, indicating a similarity of 45% and 55% to the pattern of the two clustering isolates. Interestingly, the two isolates of the same PFGE pattern were both from dogs and isolated within the same year, but it could be the result of a random effect (Figure 2).

Antimicrobial susceptibility testing

All isolates showed microbiological resistance to third-generation cephalosporins, and also clinical resistance, either when the MIC results were interpreted according to clinical breakpoints set by CLSI [16] or by EUCAST (e. g. MIC cefotaxime ≥ 4mg/L), except for 9KP (MIC 1 mg/L). The phenotype for PMQR was evident (ciprofloxacin MIC 0.25mg/L, nalidixic acid 8 mg/L) in KO isolates only, because in all KP isolates it was masked by concurrent genetic background conferring Mics of 8 and 128 mg/L, respectively.

Moreover, all isolates showed multidrug-resistance towards other classes of antimicrobials, such as aminoglycosides, sulfonamides, tetracyclines, dihydrofolate reductase inhibitors and amphenicols, mediated by <i>strA/B</i>, <i>adaA2</i>, <i>adaB</i>, <i>ant (2’)-Ia</i>, <i>aac(6’)-Ib</i>, sul, tet, dfr and cat genes in various combinations, as reported in Table 1.

Genes encoding ESBL-, AmpC-, and PMQR

All <i>Klebsiella</i> isolates investigated showed the presence of at least one ESBL or AmpC gene encoding ESC resistance. Additionally, 16 out of 19 isolates harbored a PMQR gene (<i>qnr</i> family or <i>aac(6’)-Ib-cr</i>, single or in combination). The most frequent ESC gene harbored by KP isolates was <i>bla<sub>CTX-M-15</sub></i> (n = 11, 58%), detected in all eight ST101, in one ST13 and in both two ST340 isolates, respectively. All four ST15 KP isolates carried the <i>bla<sub>SHV-28</sub></i> gene, single or in combination with the ESC resistance genes <i>bla<sub>CTX-M-15</sub></i>.
based on nemase genes. bla presented the IncR plasmid carrying different ESBL genes such as bla, the IncR plasmid carrying the bla group, and in the 18KP transconjugant the were positive for plasmids belonging to the IncR incompatibility 16KP strain. The paper provides evidence of heterogeneity of determinants in our study, the bla transformants carried the ESBL genes, blaCTX-M-9 and blaSHV-12 in two incompatibility groups, IncHI2 and IncL/M, respectively (Table 1).

Plasmid analysis

Plasmids detected from all the strains and classified by the PCR-based replicon typing method, are reported in Table 1. In our study, the blaCTX-M-15 gene was successfully transferred by transformation from several MLST prototypic strains, demonstrating its plasmid localization. All but one transformant strains were positive for plasmids belonging to the IncR incompatibility group, and in the 18KP transconjugant the blaCTX-M-15 gene was co-transferred with the blaTEM-1, blaGNA-1 and the blaSHV-1, or blaSHV-11 or blaSHV-28 (Table 1).

Of the four KO isolates, two were positive for blaCTX-M-9 gene, both associated with the PMQR gene qnrA1, with one the two also positive for the qnrA mutant detected for the first time in China in 2002 (GenBank AF538324), and previously reported to encode for an ESBL phenotype [32]. Co-preservation of blaCTX-M-15 and blaSHV-28 has been reported for the first time in the human KP ST15 epidemic clone by Nielsen et al., in 2011 [33]. Our transformation experiments did not succeed in transferring any of the blaSHV28 genes from positive KP isolates.

Interestingly, all KP ST15 isolates showed the association of the blaCTX-M-15, blaCTX-M-1, or blaCTX-M-2 genes with the blaSHV-28 gene, a blaSHV-1 mutant detected for the first time in China in 2002 (GenBank AF538324), and previously reported to encode for an ESBL phenotype [32]. Co-preservation of blaCTX-M-15 and blaSHV-28 has been reported for the first time in the human KP ST15 epidemic clone by Nielsen et al., in 2011 [33]. Our transformation experiments did not succeed in transferring any of the blaSHV28 genes from positive KP isolates.

The multidrug-resistant CTX-M-15-producing KP isolates are an of important concern in the nosocomial infections and the practitioner in 2010 and 2011, respectively. We also document the novel finding of the co-existence of the ESBL and AmpC blaCMY-2 gene in one KP ST15 isolate from a cat and the first report of qnrS- and qnrA- associated with Klebsiella infections in companion animals from Europe. Klebsiella with ESBL phenotype were described in dogs and cats from China [12], although it was mediated in those isolates by the presence of the CTX-M-9 and CTX-M-1 group beta-lactamases, while a CTX-M-15 positive ST15 KP clone was reported from hospital-acquired infections in pets from France [31]. In our study, the ESBL gene blaCTX-M-15 accounts for the majority of CTX-M genes detected in KP, but it was harbored mainly by the predominant KP ST101 lineage.

Interestingly, all KP ST15 isolates showed the association of the blaCTX-M-15, blaCTX-M-1, or blaCTX-M-2 genes with the blaSHV-28 gene, a blaSHV-1 mutant detected for the first time in China in 2002 (GenBank AF538324), and previously reported to encode for an ESBL phenotype [32]. Co-preservation of blaCTX-M-15 and blaSHV-28 has been reported for the first time in the human KP ST15 epidemic clone by Nielsen et al., in 2011 [33]. Our transformation experiments did not succeed in transferring any of the blaSHV28 genes from positive KP isolates.

The multidrug-resistant CTX-M-15-producing KP isolates are an of important concern in the nosocomial infections and the practitioner in 2010 and 2011, respectively. We also document the novel finding of the co-existence of the ESBL and AmpC blaCMY-2 gene in one KP ST15 isolate from a cat and the first report of qnrS- and qnrA- associated with Klebsiella infections in companion animals from Europe. Klebsiella with ESBL phenotype were described in dogs and cats from China [12], although it was mediated in those isolates by the presence of the CTX-M-9 and CTX-M-1 group beta-lactamases, while a CTX-M-15 positive ST15 KP clone was reported from hospital-acquired infections in pets from France [31]. In our study, the ESBL gene blaCTX-M-15 accounts for the majority of CTX-M genes detected in KP, but it was harbored mainly by the predominant KP ST101 lineage.

Interestingly, all KP ST15 isolates showed the association of the blaCTX-M-15, blaCTX-M-1, or blaCTX-M-2 genes with the blaSHV-28 gene, a blaSHV-1 mutant detected for the first time in China in 2002 (GenBank AF538324), and previously reported to encode for an ESBL phenotype [32]. Co-preservation of blaCTX-M-15 and blaSHV-28 has been reported for the first time in the human KP ST15 epidemic clone by Nielsen et al., in 2011 [33]. Our transformation experiments did not succeed in transferring any of the blaSHV28 genes from positive KP isolates.
<table>
<thead>
<tr>
<th>Sequence Type</th>
<th>Key</th>
<th>Antimicrobial Resistance profile</th>
<th>Plasmid</th>
<th>ESBL and AmpC genes</th>
<th>PMQR genes</th>
<th>Other resistance and Integron genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>2KP</td>
<td>AMP, CTX, CFT, NAL, CIP, STR, KAN, CLO, SULFA, TRI, TET</td>
<td>IncI1; IncR</td>
<td>blaCTX-M-1, blaSHV-2a,</td>
<td>aac(6'9)-Ib-cr</td>
<td>aadA2; catA1; dfrA12; sul1; tet(A); intI1</td>
</tr>
<tr>
<td>15</td>
<td>9KP</td>
<td>AMP, CTX, CFT, NAL, CIP, STR, KAN, GEN, CLO, SULFA, TRI, TET</td>
<td>IncR; IncFIIk</td>
<td>blaSHV-1, blaoxytoca-28, blaTEM-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>strA/B; catA1; dfrA12; sul1; tet(A); intI1</td>
</tr>
<tr>
<td>15</td>
<td>7KP</td>
<td>AMP, CTX, CFT, NAL, CIP, STR, KAN, SULFA, TRI</td>
<td>IncR</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>strA/B; dfrA14; sul1; intI1</td>
</tr>
<tr>
<td>15</td>
<td>13KP</td>
<td>AMP, CTX, CFT, NAL, CIP, STR, KAN, GEN, CLO, SULFA, TRI, TET</td>
<td>IncN; IncFIIk; IncFIA; IncFIB; IncR</td>
<td>blaCTX-M-1, blaoxytoca-28,</td>
<td>aadA2; strA/B; catA1; dfrA12; sul1; intI1</td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>10KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, SULFA, TRI, TET</td>
<td>IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; dfrA17; tet(D)</td>
</tr>
<tr>
<td>101</td>
<td>3KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, TRI</td>
<td>IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; dfrA17; tet(D)</td>
</tr>
<tr>
<td>101</td>
<td>5KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, TRI</td>
<td>IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; dfrA17; tet(D)</td>
</tr>
<tr>
<td>101</td>
<td>6KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, TRI</td>
<td>IncH1; IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; dfrA17; tet(D)</td>
</tr>
<tr>
<td>101</td>
<td>4KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, TRI</td>
<td>IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; dfrA17; tet(D)</td>
</tr>
<tr>
<td>101</td>
<td>15KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, SULFA, TRI, TET</td>
<td>IncH2; IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; dfrA17; tet(D)</td>
</tr>
<tr>
<td>101</td>
<td>1KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, SULFA, TRI, TET</td>
<td>IncH2; IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; dfrA17; tet(D)</td>
</tr>
<tr>
<td>340</td>
<td>17KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, SULFA, TRI, TET</td>
<td>IncH2; IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1, qnrS1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; qnrS1; tet(A); intI1</td>
</tr>
<tr>
<td>340</td>
<td>18KP</td>
<td>AMP, CTX, CFT, NAL, CIP, KAN, GEN, SULFA, TRI, TET</td>
<td>IncR; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1, qnrS1</td>
<td>aac(6'9)-Ib-cr</td>
<td>aac(6'9)-Ib-cr; qnrS1; tet(A); intI1</td>
</tr>
<tr>
<td>11</td>
<td>16KP</td>
<td>AMP, CTX, CFT, NAL, CIP, SULFA, TRI, TET</td>
<td>IncN; IncFIIk; IncFII</td>
<td>blaCTX-M-15, blaoxytoca-28, blaTEM-1, blaOXA-1</td>
<td>qnrS1</td>
<td>aac(6'9)-Ib-cr; aadA2; dfrA1; sul1; tet(A)</td>
</tr>
<tr>
<td>NA</td>
<td>3A KO</td>
<td>AMP, CTX, CFT, STR, KAN, SULFA, TRI, TET</td>
<td>IncH2; IncLM</td>
<td>blaoxytoca-12, blaoxytoca-28, blaoxytoca-28</td>
<td>qnrB4</td>
<td>strA/B; dfrA19; sul1; tet(D); intI1</td>
</tr>
<tr>
<td>NA</td>
<td>4A KO</td>
<td>AMP, CTX, CFT, STR, KAN, SULFA, TRI, TET</td>
<td>IncH2; IncLM</td>
<td>blaoxytoca-12, blaoxytoca-28, blaoxytoca-28</td>
<td>qnrB4</td>
<td>strA/B; dfrA19; sul1; tet(D); intI1</td>
</tr>
<tr>
<td>NA</td>
<td>1A KO</td>
<td>AMP, CTX, CIP, SULFA, TRI, TET</td>
<td>IncH2; IncLM</td>
<td>blaoxytoca-28</td>
<td>qnrA1</td>
<td>aadA2; aadB; sul</td>
</tr>
<tr>
<td>NA</td>
<td>6A KO</td>
<td>AMP, CTX, CIP, SULFA, TRI, TET</td>
<td>IncH2</td>
<td>blaoxytoca-28</td>
<td>qnrA1; aac(6'9)-Ib-cr</td>
<td>aadA2; antA2; sul; intI1</td>
</tr>
</tbody>
</table>

**Legend:**
- NA: Not Applicable; AMP = Ampicillin; CTX = Ceftazidime; CIP = Ciprofloxacin; CLO = Chloramphenicol; CTX = Cefotaxime; GEN = Gentamicin; KAN = Kanamycin; NAL = Nalidixic Acid; STR = Streptomycin; SULFA = Sulfamethoxazole; TET = Tetracycline; TRI = Trimethoprim.
- Note: When underscored, plasmids and their content of beta-lactamase and PMQR genes where detected in transformant strains.
- doi:10.1371/journal.pone.0090564.t001
time in clinical cases of pets from Italy the clone KP ST11 and its SLV ST340, harboring ESC and qnr/S-PMQR resistance. Among these CC11 isolates, the ST11 harbored IncN plasmid, which has been frequently involved in the transmission of the bla<sub>CTX-M-1</sub> gene, a feature suggesting an animal reservoir for this ESBL, since this Inc plasmid types have been demonstrated to be highly prevalent in zoonotic enterobacterial pathogens [29]. The same animal origin reservoir is proposed for the IncH1 plasmids harboring the <i>bla</i><sub>IMI-2</sub> gene found in <i>E. coli</i> avian commensal strains [34].

It is noteworthy that ST11 and ST340 carried transferable ESBL resistance but not resistance to carbapenems. ST(CC)11 and ST15 and ST101 are among human epidemic clones, carrying both ESBLs and carbapenemases, which have been increasingly detected worldwide, in Europe and in Italy in the last years [36], [37], [38], [39], [40].

These infections are worrisome, since the antimicrobial treatment options for these multidrug-resistant strains are very limited. In Italy, during the last years the rapid emergence of the carbapenemase KPC-producing KP, belonging to the ST101, CC11, and predominately to a single Sequence Type ST258, has become a serious problem in health-care settings [41], [42], [43].

As for CTX-M and SHV-12 ESBLs in Italy, a high occurrence of KP isolated from humans has been demonstrated, being the ST15, ST37, ST147 and ST273 the prevalent clones [44], [45], [46], [47].

In two KO isolates, the ESBL-encoding <i>bla</i><sub>SHV-12</sub> gene co-existed with the AmpC gene <i>bla</i><sub>ROB-1</sub> in accordance with phenotype of resistance to cefotaxime and cefoxitin observed in the ESBL phenotypic confirmatory test. These two isolates also carried the PMQR gene <i>qnrB1</i>. In these two KO transformants the IncL/M plasmid harbored both the <i>bla</i><sub>SHV-12</sub> and the <i>bla</i><sub>ROB-1</sub> genes but not the <i>qnrB1</i> gene. To our knowledge, this feature has never been described before.

The other KO presented the <i>bla</i><sub>CTX-M-9</sub> gene, located in an IncHI2 plasmid as described worldwide but associated to a <i>qnrA</i> gene, a feature previously described in Spain in <i>E. coli</i> and KP of human origin [48], [49] and in KO in clinical specimens from Japan [50].

Similarly to what has been observed in other human and canine KP isolates [34], [12], the association of <i>bla</i><sub>CTX-M</sub> genes with the the <i>ace</i>(6) /<i>Bo</i>-<i>cr</i> encoding an aminoglycoside acetyl transferase determining PMQR, was demonstrated in all ST101 and ST340 isolates, but only in one out of four ST15, but these PMQR genes were not located in the same plasmid in our strains. Conversely, PMQR encoded by different <i>qnr</i> genes of the <i>qnrC</i> or <i>qnrB</i> groups were observed in all the KO isolates studied (Table 1). In the case of the <i>qnrB1</i> gene, the two KO isolates also harbored the ESBL <i>bla</i><sub>CTX-M-9</sub> gene, a feature reported previously in association with <i>bla</i><sub>NDM-1</sub> and IncHII2 plasmids in KO of human origin [51].

Multidrug-resistance in the ESC resistant and PMQR isolates studied is of further concern from a therapeutic perspective, for a possible impact on clinical outcome of affected animals. In many isolates, the demonstration of the integrase <i>intI1</i>, accounts for the presence of resistance gene cassettes with <i>ade</i>, <i>ade</i>, <i>cat</i>, <i>dfr</i> genes, associated with Class I integrons, similarly to what has been described in KP of human origin [52], [53]. As for streptomycin resistance, MIC>16 mg/L correlated in 100% isolates with the presence of <i>strA/B</i> genes.

Fortunately, the absence of carbapenemases offers so far a better scenario for antimicrobial therapy in companion animals, although a possible circulation, within a short time, of these carbapenemase-producing epidemic strains, is of concern also in veterinary medicine.

In conclusion, monitoring and characterization of multidrug-resistant <i>Klebsiella</i> in companion animals by means of phenotypic and molecular methods proved to be useful for providing a picture of mechanisms of resistance that may further spread clonally or by horizontal gene transfer, at regional or even at international level. Sharing this kind of information appears essential for building awareness in companion animal therapy, also in view of preventing and controlling the spread of multidrug-resistant strains in veterinary hospital settings. Indeed, the bi-directional exchange between owners and pets of <i>Klebsiella</i> carrying resistance to critically important antimicrobials for human health, raise some concerns also for the possibility of a spill back to humans, especially at household level.

The emergence of the PMQR and, above all, the emergence of concurrent transferable cefepimecin, oxymimo-cephalosporin, and beta-lactamase inhibitor resistance in multidrug-resistant <i>Klebsiella</i> isolates in pets, a recent issue even in human therapy [54], may pose in the next future further and serious therapeutic challenges also in bacterial infections of companion animals.

**Acknowledgments**

The Authors thank Alessandra Carattoli (ISS) for her valuable advice on how to improve the manuscript, Roberta Amoruso, Carmela Buccella, Tamara Ceri, Paola Di Matteo, Samuele Dottarelli, Angela Ianzano, Luigi Sorbara (IZSLT), and Mr. Jacob Dyring Jensen (DTU-Food) for outstanding technical assistance, and Andrea Caprioli (IZSLT) for his valuable help in editing the manuscript.

**Author Contributions**

Conceived and designed the experiments: AF AB RSH FF AGF. Performed the experiments: VD SL FF GC RL CAS. Analyzed the data: VF FF AF AB RL RSH CAS AGF. Contributed reagents/materials/analysis tools: AB AF RSH. Wrote the paper: AF AB RSH AGF.
References


